Niagen Bioscience, Inc. — Director's Dealing 2017

Dec 21, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2017-12-20

Reporting Person: Fried Robert N (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-20	Common Stock	A	333333	—	Acquired	916574	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	12744	Indirect

Footnotes

F1: On December 20, 2017, ChromaDex Corporation (the "Company") and Robert Fried entered into an amendment (the "Amendment") to Mr. Fried's existing Executive Employment Agreement, dated March 12, 2017. In connection with the Amendment, the Company granted to Mr. Fried 333,333 shares of restricted Common Stock pursuant to the Company's 2017 Equity Incentive Plan, which shares are fully-vested.

F2: Includes 166,667 shares of restricted Common Stock previously granted by the Company on March 12, 2017. In connection with the Amendment, the Company accelerated in full the vesting of the 166,667 shares of restricted Common Stock previously granted to Mr. Fried on March 12, 2017.

F3: 6,744 shares held by Jeremy Fried and 6,000 shares held by Benjamin Fried, who are both sons of Robert Fried.